Liqing Zhang1, Xiuxia Guo2, Yongzheng Min1, Jianjiang Xu3. 1. Department of Urology Surgery, General Hospital of Jinan Military Command Jinan, China. 2. Department of Gynecology, General Hospital of Jinan Military Command Jinan, China. 3. Department of Pharmacy, General Hospital of Jinan Military Command Jinan, China.
Abstract
OBJECTIVE: This study aims to investigate the application value of tumor abnormal protein (TAP) examination in the diagnosis of urothelial carcinoma of the bladder. METHOD: Abnormal sugar chain glycoproteins in the peripheral blood of 87 patients with urothelial carcinoma of the bladder were detected, and compared with non-tumor patients accompanied by hematuria. RESULT: TAP examination showed that the positive rate of the abnormal sugar chain glycoprotein in the peripheral blood of the 87 patients with urothelial carcinoma of the bladder was 78.16%, whereas that of the non-tumor patients was 10.81%. The former is significantly higher than the latter (P<0.01). CONCLUSION: TAP examination can be used to detect urothelial carcinoma of the bladder, and would be helpful in the diagnosis of urothelial carcinoma of the bladder by combining the clinical signs and symptoms.
OBJECTIVE: This study aims to investigate the application value of tumor abnormal protein (TAP) examination in the diagnosis of urothelial carcinoma of the bladder. METHOD: Abnormal sugar chain glycoproteins in the peripheral blood of 87 patients with urothelial carcinoma of the bladder were detected, and compared with non-tumorpatients accompanied by hematuria. RESULT: TAP examination showed that the positive rate of the abnormal sugar chain glycoprotein in the peripheral blood of the 87 patients with urothelial carcinoma of the bladder was 78.16%, whereas that of the non-tumorpatients was 10.81%. The former is significantly higher than the latter (P<0.01). CONCLUSION: TAP examination can be used to detect urothelial carcinoma of the bladder, and would be helpful in the diagnosis of urothelial carcinoma of the bladder by combining the clinical signs and symptoms.
Authors: Peter E Clark; Neeraj Agarwal; Matthew C Biagioli; Mario A Eisenberger; Richard E Greenberg; Harry W Herr; Brant A Inman; Deborah A Kuban; Timothy M Kuzel; Subodh M Lele; Jeff Michalski; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Jerome P Richie; Wade J Sexton; William U Shipley; Eric J Small; Philippe E Spiess; Donald L Trump; Geoffrey Wile; Timothy G Wilson; Mary Dwyer; Maria Ho Journal: J Natl Compr Canc Netw Date: 2013-04-01 Impact factor: 11.908
Authors: Vicente Guillem; Miguel Angel Climent; Javier Cassinello; Emilio Esteban; Daniel Castellano; José Luis González-Larriba; Pablo Maroto; Carlos Camps Journal: BMC Urol Date: 2015-03-13 Impact factor: 2.264